Title Page

Article Type: Research Article

Title: Potential impact of outpatient stewardship interventions on antibiotic exposures of bacterial pathogens

Authors: Christine Tedijanto,[1] Yonatan H Grad,[2,3] Marc Lipsitch[1,2]

Author Affiliations: [1] Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; [2] Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; [3] Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Corresponding Author: Christine Tedijanto, ctedijanto@g.harvard.edu

Manuscript Word Count: 3,025

Abstract

The relationship between antibiotic stewardship and population levels of antibiotic resistance remains unclear. In order to better understand shifts in selective pressure due to stewardship, we use publicly available data to estimate the effect of changes in prescribing on exposures to frequently used antibiotics experienced by potentially pathogenic bacteria that are asymptomatically colonizing the microbiome. We quantify this impact under four hypothetical stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics, have the opportunity to broadly reduce antibiotic exposures across a range of potential pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are needed to further decrease exposures occurring in “necessary” contexts.

Introduction

Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over 80% of antibiotic consumption for human health occurs in the outpatient setting (European Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden, Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013), and bystander selection for antibiotic resistance, with little to no health gains for the patient. Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when the organisms are asymptomatically colonizing the microbiome, not causing disease (Tedijanto, Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions in use will prevent antibiotic exposures for species throughout the microbiome.

We use publicly available data to quantify potentially avertable exposures of bacterial species to commonly used antibiotics under hypothetical changes in prescribing practice. The set of scenarios included here are intended as thought experiments to explore the upper bounds of avertable antibiotic exposures. Reductions in antibiotic consumption have historically had variable impacts on resistance levels, likely dependent on setting, baseline consumption and resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

57 treatment strategies are primarily guided by randomized controlled trials assessing immediate
58 clinical outcomes, with less careful consideration given to the microbiome-wide effect of such
59 decisions. We apply analytical methods to parse out species-level effects of changes in
60 prescribing practice in order to better understand the potential impact of antibiotic stewardship.
61

62 **Methods**

63 *Scenarios of interest*

64 This analysis includes sixteen antibiotics that are frequently prescribed in the outpatient setting
65 and nine potentially pathogenic bacterial species that are commonly carried in the normal human
66 microbiome. For each antibiotic-species pair, we estimate the proportion of antibiotic exposures
67 experienced by that species that could be averted under four hypothetical scenarios. The
68 scenarios range from broad elimination of unnecessary prescribing to focused modifications of
69 antibiotic use for specific indications as follows:

70 1) Eliminate unnecessary antibiotic use across all outpatient conditions.
71 2) Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics are
72 not indicated.
73 3) Eliminate all antibiotic use for acute sinusitis.
74 4) Prescribe nitrofurantoin for all cases of cystitis in women.

75 Based on previously published work, we consider viral upper respiratory tract infection,
76 influenza, non-suppurative otitis media, viral pneumonia, bronchitis, and allergy and asthma to
77 be outpatient respiratory conditions for which antibiotics are not indicated (Fleming-Dutra et al.,
78 2016). Due to the self-limiting nature and infrequent bacterial etiology of acute sinusitis, there is
79 weak evidence to support antibiotic treatment (Burgstaller, Steurer, Holzmann, Geiges, & Soyka,

80 2016; Rosenfeld et al., 2015). However, antibiotics continue to be prescribed at over 80% of US
81 outpatient visits with a primary diagnosis of acute sinusitis (Smith et al., 2013). In contrast,
82 antibiotics are always recommended for urinary tract infections (UTIs). Despite being
83 recommended as a second-line therapy for cystitis due to concerns about resistance,
84 fluoroquinolones are the most common treatment, prescribed at 40% of outpatient visits for
85 uncomplicated UTI (Kabbani et al., 2018). We explore the hypothetical scenario of treating all
86 cases of cystitis in women with nitrofurantoin, a recommended first-line therapy with good
87 potency against common uropathogens, low levels of resistance, and decreased risk of collateral
88 damage to the intestinal microbiome due to its propensity to concentrate in the bladder (Gupta et
89 al., 2011; Gupta, Scholes, & Stamm, 1999; Stewardson et al., 2015).
90
91 *Data sources and methodology*
92 Extending our recent work on bystander selection (Tedijanto et al., 2018), we used the 2015
93 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care
94 Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012;
95 The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies
96 to estimate national outpatient antibiotic exposures by drug, species, and condition.
97 NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in
98 the United States, and up to five diagnoses and thirty medications may be associated with each
99 visit. We used methodology developed by Fleming-Dutra and colleagues (Fleming-Dutra et al.,
100 2016), and applied in other studies (Olesen et al., 2018), to group diagnosis codes into conditions
101 and link antibiotic prescriptions with the most likely indication. For this analysis, visits with a
102 diagnosis of acute cystitis (ICD-9-CM: 595.0), unspecified cystitis (595.9) or unspecified UTI

103 (599.0), without a concurrent diagnosis of pyelonephritis (590.1, 590.8), renal abscess (590.2), or
104 kidney infection (590.9), were considered to be associated with cystitis. In this analysis, we
105 maintain the assumption that one antibiotic prescription is equivalent to one exposure; antibiotic
106 exposures experienced by a given species and associated with a given condition are roughly
107 estimated as the product of antibiotic prescriptions for that condition and species carriage
108 prevalence, which is dependent on disease etiology (target exposures) and asymptomatic carriage
109 prevalence (bystander exposures) (details in Appendix Table 1). For diagnoses where etiology
110 was not readily available, we assumed that none of our species of interest were causative agents.
111 These assumptions have been enumerated in detail in prior work (Tedijanto et al., 2018).
112
113 We applied proportions of unnecessary antibiotic prescribing by condition and age group
114 estimated by Fleming-Dutra and colleagues based on expert opinion, clinical guidelines, and
115 regional variability in use (Fleming-Dutra et al., 2016). Since these estimates were reported for
116 oral antibiotic use in the outpatient setting, we excluded antibiotics that are typically
117 administered topically or parenterally. For relevant scenarios (1 and 2), we applied the
118 proportions of unnecessary use evenly across all antibiotic prescriptions.
119
120 The proportion of avertable antibiotic exposures for each species is defined by Equation 1. The
121 equation adopts previously described notation (Tedijanto et al., 2018) with modifications. A
122 listing of all variables and descriptions can be found in Appendix Table 1. Let a represent
123 antibiotic, s represent species, i represent ICD-9-CM diagnosis code, and g represent age group.
124 Prescriptions with $i=0$ were not associated with any ICD-9-CM diagnosis codes, and throughout
125 the analysis we have weighted outpatient visits to be nationally representative. Let X_{as} be the

126 number of avertable exposures by antibiotic and species, T_{as} be the total number of exposures by
127 antibiotic and species, d_{aig} be the number of prescriptions of antibiotic a associated with
128 diagnosis code i in age group g, p_{sig} be the carriage prevalence of species s among those with
129 diagnosis code i in age group g, and q_{aig} be the proportion of avertable exposures by diagnosis
130 code and age group in the given scenario. For example, in the scenario assessing elimination of
131 all unnecessary antibiotic use, q_{aig} is the proportion of avertable antibiotic use by diagnosis and
132 age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing elimination of
133 non-nitrofurantoin treatment for cystitis, q_{aig} is 1 when a is not nitrofurantoin and i is a diagnosis
134 code associated with cystitis, and 0 elsewhere. Carriage prevalences (p_{sig}) are assumed to be
135 constant within three age groups (under 1 year, 1-5 years, over 5 years old) (Tedijanto et al.,
136 2018), while proportions of avertable antibiotic use (q_{aig}) were reported for three different age
137 groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-Dutra et al., 2016). G is the
138 smallest set of age groups that accounts for this granularity (under 1 year, 1-5 years, 6-19 years,
139 20-64 years, 65 years old and over).

140 **Equation 1.** Proportion of avertable exposures by species and antibiotic.

141
$$\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^{G}\sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^{G}\sum_{i=0}^{I} d_{aig} \times p_{sig}}$$

142 In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander
143 exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial
144 and non-bacterial etiologies is possible. This results in a slight modification to Equation 1 -- p_{sig}
145 is changed to p_{s0g} as all eliminated exposures would have occurred during asymptomatic
146 carriage. For cases where e_{sig} is 1, we assume zero avertable exposures. In addition, we make
147 slight modifications to q_{aig} when we estimate the proportion of bacterial cases to be larger than
148 the proportion of necessary prescriptions (Appendix Table 2). As a sensitivity analysis, we

149 include the proportion of avertable exposures for each species-antibiotic pair under Scenario 1 if
150 antibiotic use was eliminated equally across both target and bystander exposures (Appendix
151 Figure 1). All analysis was conducted in R version 3.5.1.
152
153 **Results**
154 Results for all four scenarios are depicted in Figure 1. We estimate that elimination of
155 unnecessary antibiotic prescriptions across all outpatient conditions would prevent 6 to 48%
156 (IQR: 17 to 31%) of antibiotic-species exposures (Figure 1A). The smallest reduction is
157 associated with *S. pyogenes* exposures to cefdinir and the largest with *H. influenzae* and *E. coli*
158 exposures to azithromycin. If all unnecessary antibiotic use could be prevented, over 30% of
159 exposures to amoxicillin-clavulanate, penicillin, azithromycin, clarithromycin, levofloxacin, and
160 doxycycline across most potential pathogens of interest could be averted. As expected, the
161 proportion of avertable exposures when all unnecessary outpatient use is eliminated is positively
162 correlated with previously reported estimates of bystander selection (Appendix Figure 2)
163 (Tedijanto et al., 2018).
164
165 Across all scenarios, the proportion of avertable exposures appears to be primarily driven by the
166 drug considered. For example, in both scenarios assessing broad elimination of unnecessary
167 antibiotic use, every species can expect azithromycin exposures to decrease to the greatest extent
168 as it is the most commonly used antibiotic for respiratory conditions for which antibiotics are not
169 indicated (Figure 1B). The estimated reductions in azithromycin across species range from 37 to
170 48% when all outpatient conditions are considered and from 24 to 32% when limited to the
171 subset of respiratory conditions for which antibiotics are not indicated. High estimates of

avertable exposures for a particular antibiotic reflect both frequent use for the impacted syndrome(s) and concentrated use for those conditions relative to other indications. Consider the indication-specific scenarios: ciprofloxacin and sulfamethoxazole-trimethoprim are the most frequently prescribed antibiotics for cystitis other than nitrofurantoin and have relatively large estimates of avertable exposures (23 to 44% and 7 to 26%, respectively). While clarithromycin is only the eighth-most-prescribed antibiotic for acute sinusitis among the included antibiotics, its concentrated use for acute sinusitis compared to other indications results in relatively large expected reductions in exposure (up to 9% for *P. aeruginosa* and *S. pyogenes*) compared to other drugs.



Figure 1. Heatmaps showing the estimated percentage of species exposures to each antibiotic or antibiotic class that could be averted if *A:* unnecessary antibiotic prescriptions across all outpatient conditions, *B:* all antibiotic use for outpatient respiratory conditions for which antibiotics are not indicated, *C:* all antibiotic use for acute sinusitis, or *D:* non-nitrofurantoin

treatment of cystitis in women was eliminated. Drug class results include prescriptions of all antibiotics in that class, as identified by the Multum Lexicon classification system.

Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin, AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides, CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline, TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

Characteristics of the bacterial organism of interest also influence the extent of avertable exposures. Species that are common causes of the affected condition(s) naturally have larger predicted reductions in exposure. For example, an estimated 33%, 36%, and 44% of ciprofloxacin exposures to *E. coli*, *K. pneumoniae*, and *P. aeruginosa*, respectively, could be averted under the cystitis scenario, compared to 23 to 27% across all other organisms. Although *E. coli* is the most common cause of UTIs, its estimated exposure reduction in this scenario is lower than that of *P. aeruginosa*, likely due to the larger number of bystander exposures incurred by *E. coli* during asymptomatic carriage. Infrequent carriage prevalence in the normal microbiome is also generally associated with lower proportions of avertable exposures across all antibiotics (e.g. *S. pyogenes, S. agalactiae*, *M. catarrhalis*).

Discussion

We quantify the species-level impact of changes in antibiotic consumption as the proportion of antibiotic exposures experienced by common bacterial pathogens that could be averted under four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae* and *E. coli* to azithromycin) could be avoided. In addition, impact of the intervention across antibiotics and species is widespread, with half of antibiotic-species pairs expected to experience a reduction in exposures of over one fifth (22%). For conditions which require antibiotic treatment, such as

214 UTIs, switching to antibiotics with decreased collateral damage to the microbiome, such as
215 nitrofurantoin, may be an effective strategy for reducing antibiotic exposures across species.
216
217 In three out of four situations we assess, antibiotics are considered entirely unnecessary for some
218 or all cases. This is a strong assumption in the case of acute sinusitis, as a small number of cases
219 are truly bacterial and antibiotics are indicated for patients with persistent, severe or worsening
220 symptoms (Rosenfeld et al., 2015). These scenarios are explored in sensitivity analyses
221 (Appendix Figure 3). In the future, this method may also be extended to measure net changes in
222 exposures resulting from more nuanced scenarios where one antibiotic is substituted for another.
223 We did not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the
224 bladder are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here
225 may be practically infeasible due to challenges including similar clinical presentation of viral and
226 bacterial infections, individual considerations such as allergies (Sakoulas, Geriak, & Nizet, 2018)
227 or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas, Getman, Donskey,
228 & Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even if elimination of
229 unnecessary use were fully realized, our results imply that the majority of species' antibiotic
230 exposures occur in the context of "necessary" antibiotic use. These findings underscore the
231 importance of considering bystander effects and the need for a multi-pronged approach to
232 programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics that
233 accurately discriminate between bacterial and non-bacterial causes, patient education, and
234 improved decision-making tools and other interventions to motivate changes in clinician
235 behavior can enhance responsible antibiotic consumption; these should be implemented
236 simultaneously with prevention measures such as infection control, access to clean water and

237 sanitation, safe sex interventions, and vaccination, which aim to reduce infection incidence and
238 thus any antibiotic use.
239
240 At the time of this analysis, NHAMCS data from hospital outpatient departments was not yet
241 available for years after 2011. In the 2010-2011 NAMCS/NHAMCS data, visits to hospital
242 outpatient departments accounted for 36% of included sampled visits, but just 9% of all
243 antibiotic mentions. The proportions of avertable exposures including and excluding these visits
244 for 2010-2011 were similar (Appendix Figure 4); thus, we assumed that antibiotic use and
245 diagnoses in the existing 2015 data without hospital outpatient department visits was
246 representative. Additional limitations of the included datasets and method for estimating
247 antibiotic exposures have been previously enumerated (Tedijanto et al., 2018). Notably, the
248 NAMCS/NHAMCS does not provide information to link medications with diagnoses, so we
249 adopted a published tiered system to pair antibiotic use at each visit with the most likely
250 indication (Fleming-Dutra et al., 2016). For visits with multiple diagnoses, all antibiotic use was
251 attributed to the single most-likely indication. This method tends to overestimate antibiotic use
252 for conditions for which antibiotics are almost always indicated, which may lead to clinically
253 unusual diagnosis-treatment linkages. In the same way, antibiotic prescriptions are
254 underestimated for diagnoses for which antibiotic use is not indicated, potentially leading to
255 downward bias in avertable exposures for these conditions. Additionally, NAMCS/NHAMCS
256 antibiotic use data does not include prescription details such as duration or dose. However, the
257 correlation between these factors and selection for resistance requires further study; prescriptions
258 may be a sufficient measure (Bruyndonckx et al., 2014; Lipsitch, 2001).
259

260 At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of
261 unnecessary antibiotic prescribing by condition. Recent work with slightly different methods
262 found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to
263 30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable
264 estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that
265 declines in antibiotic use from approximately 2011 to 2016 in the United States have been
266 primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary
267 prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts,
268 & Hicks, 2019; Klevens et al., 2019; Olesen et al., 2018). Finally, we assume that the proportion
269 of unnecessary use is constant across antibiotics used for the same condition as it is difficult to
270 identify specific antibiotic prescriptions that were unwarranted without detailed chart review. A
271 study among outpatients in the Veterans Affairs medical system found that among prescriptions
272 for community-acquired pneumonia, sinusitis, and acute exacerbations of chronic bronchitis, the
273 highest proportion of macrolide use was inappropriate (27%), followed by penicillins (22%) and
274 quinolones (12%) (Tobia, Aspinall, Good, Fine, & Hanlon, 2008). Similar studies are needed to
275 understand which antibiotics are frequently used inappropriately for other indications and
276 settings.
277
278 Reductions in antibiotic consumption are necessary to preserve the potency of these drugs.
279 Quantifying changes in species-level exposures due to stewardship programs is one more step
280 towards understanding how changes in antibiotic use correspond to antibiotic resistance at the
281 population level. Further research, integrating knowledge from clinical, ecological, and
282 evolutionary spheres, is needed to elucidate this relationship (MacLean & San Millan, 2019).

The methods presented here may be easily extended to incorporate other data sources, such as claims, or to assess more specific stewardship programs. We show that while improved prescribing practices have the potential to prevent antibiotic exposures experienced by bacterial species throughout the microbiome, complementary efforts to facilitate appropriate antibiotic consumption and decrease overall infection incidence are required to substantially avert exposures.

Acknowledgements
We thank Dr. Lauri Hicks for her helpful comments on this manuscript.

Competing Interests
ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and research grants through Harvard School of Public Health from Pfizer and PATH. YHG has received consulting income from Merck and GlaxoSmithKline. The authors have no other relationships or activities that could appear to have influenced the submitted work.

Funding Sources
This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study, Center for Communicable Disease Dynamics) from the National Institute of General Medical Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Department of Health and Human Services, or the Doris Duke Charitable Foundation.

References

Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed Up by Primary Care Pediatricians. *Archives of Pediatrics & Adolescent Medicine*, *152*(3), 244–248. https://doi.org/10.1001/archpedi.152.3.244

Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse resistance? *Nature Reviews Microbiology*, *8*(4), 260–271. https://doi.org/10.1038/nrmicro2319

Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: Summary of the Agency for Health Care Policy and Research evidence-based report. *Otolaryngology–Head and Neck Surgery*, *122*(1), 1–7. https://doi.org/10.1016/S0194-5998(00)70135-5

Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media pathogens. *The Pediatric Infectious Disease Journal*, *11*(8), S7–S11. https://doi.org/10.1097/00006454-199208001-00002

Brook, I. (2016). Microbiology of chronic rhinosinusitis. *European Journal of Clinical Microbiology & Infectious Diseases*, *35*(7), 1059–1068. https://doi.org/10.1007/s10096-016-2640-x

Bruyndonckx, R., Hens, N., Aerts, M., Goossens, H., Molenberghs, G., & Coenen, S. (2014). Measuring trends of outpatient antibiotic use in Europe: Jointly modelling longitudinal data in defined daily doses and packages. *Journal of Antimicrobial Chemotherapy*, *69*(7), 1981–1986. https://doi.org/10.1093/jac/dku063

333 Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against
334 intestinal pathogens. *Nature Reviews Immunology*, *13*(11), 790–801.
335 https://doi.org/10.1038/nri3535
336 Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic
337 efficacy in patients with a moderate probability of acute rhinosinusitis: A systematic
338 review. *European Archives of Oto-Rhino-Laryngology*, *273*(5), 1067–1077.
339 https://doi.org/10.1007/s00405-015-3506-z
340 Celin, S. E. (1991). Bacteriology of Acute Otitis Media in Adults. *JAMA*, *266*(16), 2249–2252.
341 https://doi.org/10.1001/jama.266.16.2249
342 Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic
343 prescribing among privately insured US patients: ICD-10-CM based cross sectional
344 study. *BMJ*, *364*(k5092). https://doi.org/10.1136/bmj.k5092
345 Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., &
346 Fraser, V. J. (2018). Outpatient Antibiotic Prescription Trends in the United States: A
347 National Cohort Study. *Infection Control & Hospital Epidemiology*, *39*(5), 584–589.
348 https://doi.org/10.1017/ice.2018.26
349 European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption:*
350 *Annual epidemiological report for 2017*. Stockholm.
351 Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R.
352 (2015). Diagnostic Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control*
353 *& Hospital Epidemiology*, *36*(8), 949–956. https://doi.org/10.1017/ice.2015.113
354 Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., …
355 Hicks, L. A. (2016). Prevalence of Inappropriate Antibiotic Prescriptions Among US

356 Ambulatory Care Visits, 2010-2011. *JAMA*, *315*(17), 1864–1873.
357 https://doi.org/10.1001/jama.2016.4151
358 Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., … Soper, D. E.
359 (2011). International Clinical Practice Guidelines for the Treatment of Acute
360 Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious
361 Diseases Society of America and the European Society for Microbiology and Infectious
362 Diseases. *Clinical Infectious Diseases*, *52*(5), e103–e120.
363 https://doi.org/10.1093/cid/ciq257
364 Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial
365 resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA*,
366 *281*(8), 736–738. https://doi.org/10.1001/jama.281.8.736
367 Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., …
368 White, O. (2012). Structure, function and diversity of the healthy human microbiome.
369 *Nature*, *486*(7402), 207–214. https://doi.org/10.1038/nature11234
370 Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A.
371 (2018). Opportunities to Improve Fluoroquinolone Prescribing in the United States for
372 Adult Ambulatory Care Visits. *Clinical Infectious Diseases*, *67*(1), 134–136.
373 https://doi.org/10.1093/cid/ciy035
374 Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for
375 microbial infections. *Current Opinion in Microbiology*, *16*(2), 221–227.
376 https://doi.org/10.1016/j.mib.2013.03.009

377 King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019).
378 Changes in US Outpatient Antibiotic Prescriptions from 2011-2016. *Clinical Infectious*
379 *Diseases*. https://doi.org/10.1093/cid/ciz225
380 Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019).
381 Outpatient antibiotic prescribing in Massachusetts, 2011-2015. *Open Forum Infectious*
382 *Diseases*, *6*(5), ofz169. https://doi.org/10.1093/ofid/ofz169
383 Linder, J. A. (2008). *Editorial Commentary:* Antibiotics for Treatment of Acute Respiratory
384 Tract Infections: Decreasing Benefit, Increasing Risk, and the Irrelevance of
385 Antimicrobial Resistance. *Clinical Infectious Diseases*, *47*(6), 744–746.
386 https://doi.org/10.1086/591149
387 Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, *9*(9),
388 438–444. https://doi.org/10.1016/S0966-842X(01)02130-8
389 MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. *Science*,
390 *365*(6458), 1082–1083. https://doi.org/10.1126/science.aax3879
391 Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in
392 outpatient antibiotic prescribing practice among US older adults, 2011-2015: An
393 observational study. *BMJ*, *362*, k3155. https://doi.org/10.1136/bmj.k3155
394 Public Health Agency of Canada. (2018). *Canadian Antimicrobial Resistance Surveillance*
395 *System 2017 Report*.
396 Public Health England. (2017). *English Surveillance Programme for Antimicrobial Utilisation*
397 *and Resistance (ESPAUR) 2017*.
398 Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper,
399 M., … Corrigan, M. D. (2015). Clinical Practice Guideline (Update): Adult Sinusitis.

400 *Otolaryngology–Head and Neck Surgery*, *152*(2_suppl), S1–S39.
401 https://doi.org/10.1177/0194599815572097
402 Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient
403 Grounds to Forgo the Multidimensional Antimicrobial Benefits of β-Lactam Antibiotics?
404 *Clinical Infectious Diseases*, *68*, 157–164. https://doi.org/10.1093/cid/ciy557
405 Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis:
406 Continuing Challenges and Current Management. *Clinical Infectious Diseases*,
407 *39*(Supplement_3), S151–S158. https://doi.org/10.1086/421353
408 Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits
409 for Antibiotic-Associated Adverse Events. *Clinical Infectious Diseases*, *47*(6), 735–743.
410 https://doi.org/10.1086/591126
411 Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013).
412 National burden of antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical*
413 *Immunology*, *132*(5), 1230–1232. https://doi.org/10.1016/j.jaci.2013.07.009
414 Snow, V., Mottur-Pilson, C., Hickner, J. M., & for the American College of Physicians–
415 American Society of Internal Medicine*. (2001). Principles of Appropriate Antibiotic
416 Use for Acute Sinusitis in Adults. *Annals of Internal Medicine*, *134*(6), 495.
417 https://doi.org/10.7326/0003-4819-134-6-200103200-00016
418 Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de
419 Tejada, B., … Lazarevic, V. (2015). Collateral damage from oral ciprofloxacin versus
420 nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut
421 microbiota. *Clinical Microbiology and Infection*, *21*(4), 344.e1-344.e11.
422 https://doi.org/10.1016/j.cmi.2014.11.016

Swedres-Svarm. (2017). *Consumption of antibiotics and occurrence of antibiotic resistance in Sweden*. Public Health Agency of Sweden and National Veterinary Institute.

Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. *Proceedings of the National Academy of Sciences*, *115*(51), E11988–E11995. https://doi.org/10.1073/pnas.1810840115

The Human Microbiome Project Consortium. (2012). A framework for human microbiome research. *Nature*, *486*(7402), 215–221. https://doi.org/10.1038/nature11209

Tobia, C., Aspinall, S., Good, C., Fine, M., & Hanlon, J. (2008). Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: A cross-sectional study. *Clinical Therapeutics*, *30*(6), 1135–1144. https://doi.org/10.1016/j.clinthera.2008.06.009

Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women Presenting to an Emergency Department. *Journal of Clinical Microbiology*, *53*(8), 2686–2692. https://doi.org/10.1128/JCM.00670-15

Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., … Besser, R. E. (2003). Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*, *9*(9), 1128–1135. https://doi.org/10.3201/eid0909.020591

Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young Children: Duration of and Frequency of Complications. *Pediatrics*, *87*(2), 129–133.

Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for Sinusitis. *Annals of Internal Medicine*, *117*(9), 705–710. https://doi.org/10.7326/0003-4819-117-9-705

449 **Supplementary Materials**
450
451 **Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of
452 bacterial pathogens
453
454 **Authors:** Christine Tedijanto, Yonatan H. Grad, Marc Lipsitch
455
456 **Appendix Table 1.** Notation, descriptions, and sources for variables in Equation 1.
457
458 **Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based
459 on published etiology studies. Modifications were made if the reported proportion of bacterial
460 cases for a given condition exceeded the estimated proportion of appropriate prescriptions
461 reported in Fleming-Dutra et al.
462
463 **Appendix Figure 1.** Sensitivity analysis of proportions of avertable exposures across all
464 outpatient conditions when proportion of unnecessary use is applied equally across target and
465 bystander exposures.
466
467 **Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient
468 conditions is eliminated against proportion of bystander exposures.
469
470 **Appendix Figure 3.** Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for
471 acute sinusitis).
472
473 **Appendix Figure 4.** Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS
474 data with and without NHAMCS outpatient department data.
475

476 **Appendix Table 1.** Notation, descriptions, and sources for variables in Equation 1.

Variable	Definition	Source
d_{aig}	Number of prescriptions (using nationally representative weights) of antibiotic *a* associated with ICD9-CM diagnosis code *i* in age group *g*	NAMCS/NHAMCS 2015
e_{sig}	Proportion of cases of condition defined by ICD9-CM diagnosis code *i* in age group *g* caused by species *s*	Published etiology studies
p_{s0g}	Asymptomatic carriage prevalence of species *s* in age group *g*	Human Microbiome Project (HMP) and published carriage studies
p_{sig}	Carriage prevalence of species *s* among individuals diagnosed with ICD9-CM code *i* in age group *g*	$e_{sig} + (1 - e_{sig})p_{s0g}$
q_{aig}	Proportion of prescriptions of antibiotic *a* associated with ICD9-CM diagnosis code *i* in age group *g* that are avertable under the given scenario	Fleming-Dutra et al. 2016 (Fleming-Dutra et al., 2016); note that this variable is only dependent on *a* in the nitrofurantoin-specific scenario
X_{as}	Number of exposures of antibiotic *a* experienced by species *s* that are avertable under the given scenario	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}$
T_{as}	Total number of exposures of antibiotic *a* experienced by species *s*	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}$

477
478

479 **Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based
480 on published etiology studies and antibiotic use in NAMCS/NHAMCS. Modifications were
481 made if the reported proportion of bacterial cases for a given condition exceeded the estimated
482 proportion of appropriate prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al.,
483 2016)

Age group	Fleming-Dutra estimate	New estimate	Explanation
Pharyngitis			
0-19 years old	34%	Pharyngitis: 48%; Strep throat: 0%	Assuming that all strep-associated use of our antibiotics of interest (based on NAMCS/NHAMCS) was necessary, we estimated the proportion of non-strep pharyngitis antibiotic use that would have to be eliminated to maintain the overall estimate reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016)
20-64 years old	75%	Updated to 58% overall; Pharyngitis: 100%; Strep throat: 0%	
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.
Sinusitis			
0-19 years old	9%	Acute: 16%; Chronic: 0%	While acute sinusitis is rarely bacterial, bacteria are believed to play a much more prominent role in the etiology of chronic sinusitis (Brook, 2016). Thus, we assume that antibiotic use would only be eliminated from acute sinusitis and maintain the overall estimate of unnecessary use reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016) when possible.
20-64 years old	51%	Updated to 40% overall; Acute: 100%; Chronic: 0%	
>64 years old	16%	Acute: 34%; Chronic: 0%	
Suppurative otitis media			
0-19 years old	10%	10%	No change. Approximately 84% of pediatric cases were found to have bacterial growth (Bluestone, Stephenson, & Martin, 1992), so 10% is a reasonable estimate for avertable use.
20-64 years old	33%	26%	Based on an etiology study in adults, only 26% of cases were found to have no bacterial growth (Celin, 1991).
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.

484
485

Appendix Figure 1. Sensitivity analysis of proportions of avertable exposures across all outpatient conditions when proportion of unnecessary use is applied equally across target and bystander exposures (Equation 1 without modification).



Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin, AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides, CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline, TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

499 **Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient
500 conditions is eliminated against proportion of bystander exposures (Tedijanto et al., 2018).
501



502
503
504

Appendix Figure 3. Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for acute sinusitis).

A. Use estimates of bacterial etiology to approximate appropriate antibiotic use for acute sinusitis. The following upper bound estimates for the proportion of acute sinusitis cases with bacterial etiology were used: 2% for adults and 13% for children (applied to 0-19 year old age group) (Sande & Gwaltney, 2004; Snow, Mottur-Pilson, Hickner, & for the American College of Physicians–American Society of Internal Medicine*, 2001; Wald, Guerra, & Byers, 1991).

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	3	3	3	2	3	3	3	3	1	30.6
AMX-CLAV	13	13	12	4	14	12	10	12	6	62.4
PEN										0.0
PENICILLINS	6	6	5	3	6	5	4	5	3	**93.2**
AZM	5	5	4	2	5	4	4	4	4	44.9
CLI										0.0
CLR	8	8	7	3	9	8	7	8	8	4.4
MACR/LINC	4	4	3	2	4	3	3	3	3	**51.1**
CIP	1	1	1	1	1	1	1	1	1	6.8
LEV	4	4	4	4	3	4	4	4	4	12.2
MXF	1	1	1	0.2	1	1	0.4	1	1	0.4
QUINOLONES	2	2	2	1	1	2	2	2	2	**19.6**
CFL	1	1	1	7	1	1	2	2	1	4.2
CDR	4	4	3	4	2	3	4	4	1	4.9
CEPHALOSPORINS	1	1	1	4	1	1	2	1	0.4	**11.1**
DOX	4	4	4	4	4	4	4	4	3	9.8
TET										0.0
MNO										0.0
TETRACYCLINES	2	3	2	2	2	2	2	3	2	**9.8**
TMP-SMX	1	1	1	0.3	1	1	1	1	1	3.7
NIT	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.4

B. Use estimates of bacterial etiology among those presenting to primary care clinics. Patients visiting the clinic are likely to have more persistent, severe, or worsening symptoms, which may be indications of bacterial etiology. Studies have estimated that approximately 38% of adults and 17% of children (upper bounds) visiting primary care for symptoms of acute upper respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger, Holzer, & Lau, 2000; Williams, Simel, Roberts, & Samsa, 1992).

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	3	3	2	2	3	3	2	3	1	30.6
AMX-CLAV	10	10	9	4	11	9	7	9	5	62.4
PEN										0.0
PENICILLINS	5	5	4	2	5	4	4	4	2	**93.2**
AZM	3	3	3	2	3	3	3	3	2	44.9
CLI										0.0
CLR	5	5	4	2	5	5	5	5	5	4.4
MACR/LINC	2	2	2	1	2	2	2	2	2	**51.1**
CIP	1	1	1	1	1	1	1	1	1	6.8
LEV	2	3	2	2	2	3	3	3	3	12.2
MXF	0.3	0.4	0.3	0.1	0.4	0.3	0.3	0.3	0.3	0.4
QUINOLONES	1	1	1	1	1	1	1	1	1	**19.6**
CFL	1	1	1	6	0.5	1	2	2	0.5	4.2
CDR	3	3	3	4	2	3	4	4	1	4.9
CEPHALOSPORINS	1	1	1	4	1	1	1	1	0.3	**11.1**
DOX	2	2	2	2	2	2	2	2	2	9.8
TET										0.0
MNO										0.0
TETRACYCLINES	2	2	2	1	2	2	2	2	2	**9.8**
TMP-SMX	1	1	0.4	0.2	0.4	0.5	0.4	0.5	0.5	3.7
NIT	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4

Percent of exposures averted

0 | >0 | ≥5 | ≥10 | ≥15 | ≥20 | ≥25 | ≥30 | ≥35 | ≥40 | ≥45 | ≥50 | NA

Antibiotic classes

Penicillins, Cephalosporins, Tetracyclines, Macrolides/lincosamides, Sulfamethoxazole-trimethoprim, Quinolones, Nitrofurantoin

521 **Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
522 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
523 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
524 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):*
525 EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*,
526 SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

527 **Appendix Figure 4.** Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS
528 data with *(left)* and without *(right)* NHAMCS outpatient department data.

529 **A. Eliminate unnecessary antibiotic use across all outpatient conditions.**

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	33	33	30	26	32	30	29	29	13	948.8
AMX-CLAV	37	36	35	30	35	33	30	34	21	413.8
PEN	37	37	37	32	37	36	35	37	6	114.2
PENICILLINS	34	34	32	27	33	31	29	31	13	**1519.6**
AZM	53	53	51	43	52	49	46	50	38	933.1
CLI	22	23	22	24	21	20	21	23	19	177.7
CLR	47	47	44	29	46	42	38	45	40	76.7
MACR/LINC	47	47	45	40	46	43	41	45	35	**1288.7**
CIP	15	17	14	16	12	16	16	16	15	449.2
LEV	26	27	24	20	23	25	23	26	23	191.5
MXF	36	36	34	27	35	33	31	34	30	176.3
QUINOLONES	21	23	21	22	18	22	21	22	20	**896.9**
CFL	25	25	25	29	22	23	24	25	15	431.7
CDR	29	29	28	24	25	27	25	26	15	199.4
CEPHALOSPORINS	26	26	26	24	23	24	24	25	16	**1022.4**
DOX	27	28	27	24	26	26	26	27	24	287.0
TET	19	19	19	17	18	18	17	19	17	23.2
MNO	22	22	22	22	22	22	22	22	22	66.1
TETRACYCLINES	26	26	26	23	25	25	25	26	23	**379.6**
TMP-SMX	17	18	17	22	13	16	18	18	14	466.7
NIT	9	11	9	12	7	11	11	11	11	149.3

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	33	33	30	26	32	30	29	29	13	857.5
AMX-CLAV	37	37	36	30	35	33	31	34	21	381.2
PEN	37	37	37	32	37	36	35	37	6	105.1
PENICILLINS	34	34	32	27	33	31	29	31	13	**1384.3**
AZM	53	53	51	43	52	49	46	50	38	852.6
CLI	23	23	23	24	21	21	22	23	19	163.2
CLR	48	47	45	29	47	43	38	46	40	69.7
MACR/LINC	47	47	45	40	46	43	42	45	35	**1179.9**
CIP	15	17	14	15	12	16	16	16	16	412.0
LEV	25	27	24	20	22	25	23	26	23	179.2
MXF	36	36	34	28	36	34	32	35	30	165.5
QUINOLONES	22	23	21	22	18	22	21	23	20	**830.8**
CFL	25	25	25	29	22	23	24	26	15	400.8
CDR	29	29	28	24	24	27	25	25	15	184.8
CEPHALOSPORINS	26	26	26	24	23	24	24	25	16	**948.1**
DOX	27	28	27	25	26	26	26	27	24	261.4
TET	19	19	19	17	19	18	17	19	17	21.2
MNO	22	22	22	21	22	22	22	22	22	62.7
TETRACYCLINES	26	26	26	23	25	25	25	26	23	**347.5**
TMP-SMX	17	18	17	22	13	16	17	18	14	421.1
NIT	9	11	9	12	7	11	11	11	11	136.7

530

531 **B. Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics**
532 **are not indicated.**

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	12	12	12	12	11	12	12	12	4	115.8
AMX-CLAV	16	16	17	19	14	15	15	16	8	63.9
PEN	4	4	3	2	4	3	3	3	1	4.2
PENICILLINS	13	13	13	14	11	12	12	12	4	**186.8**
AZM	36	36	35	32	35	34	32	34	25	340.2
CLI	2	2	2	5	2	2	3	3	2	3.6
CLR	28	28	27	18	28	26	23	27	24	21.8
MACR/LINC	29	29	29	28	28	27	27	28	21	**377.9**
CIP	6	6	5	7	4	6	6	6	6	28.2
LEV	12	12	11	9	10	11	11	12	11	23.9
MXF	21	21	19	14	21	19	18	20	17	36.8
QUINOLONES	10	10	9	11	8	10	10	10	9	**92.6**
CFL	6	6	7	10	5	6	6	6	3	24.7
CDR	13	13	15	13	10	13	13	13	6	26.1
CEPHALOSPORINS	9	9	10	11	7	9	9	9	5	**90.3**
DOX	11	11	10	10	10	10	10	11	9	30.4
TET	3	3	3	3	3	3	3	3	3	0.8
MNO	2	2	2	3	2	2	2	2	2	1.5
TETRACYCLINES	9	9	9	8	8	8	8	9	8	**32.9**
TMP-SMX	3	3	4	7	2	3	4	4	2	13.8
NIT	3	3	2	3	2	3	3	3	3	4.5

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	13	12	12	13	11	12	12	12	4	104.7
AMX-CLAV	17	17	18	20	14	15	16	17	9	61.0
PEN	4	4	4	2	4	4	3	3	1	4.0
PENICILLINS	13	13	13	14	11	12	12	13	5	**172.5**
AZM	37	36	36	32	36	34	32	35	26	313.1
CLI	2	2	2	5	2	2	3	3	2	3.4
CLR	29	29	28	17	29	26	23	28	25	20.4
MACR/LINC	30	30	29	28	28	28	27	29	22	**348.9**
CIP	6	6	6	6	5	6	6	6	6	26.4
LEV	12	12	11	9	10	11	11	12	11	22.2
MXF	22	21	20	14	22	20	18	20	18	36.1
QUINOLONES	10	11	10	11	8	10	10	11	9	**88.0**
CFL	6	6	7	10	5	6	6	7	3	23.8
CDR	13	13	15	13	10	13	13	12	6	23.5
CEPHALOSPORINS	9	9	10	11	7	9	9	9	5	**84.6**
DOX	10	11	10	9	10	10	10	11	9	27.7
TET	4	4	3	3	3	3	3	4	3	0.8
MNO	2	2	2	3	2	2	2	2	2	1.4
TETRACYCLINES	9	9	8	8	8	8	8	9	8	**29.8**
TMP-SMX	3	3	4	8	2	3	4	4	2	12.1
NIT	3	3	2	3	2	3	3	3	3	4.2

533

534 **C. Eliminate all antibiotic use for acute sinusitis.**

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	6	6	5	3	7	5	5	5	3	65.2
AMX-CLAV	8	8	6	2	8	7	5	6	5	35.2
PEN	1	1	1	0.5	1	1	1	1	0.2	1.4
PENICILLINS	6	6	5	3	7	5	4	5	3	**102.0**
AZM	6	6	5	3	6	5	5	5	4	57.0
CLI	2	2	1	1	1	1	1	1	1	2.8
CLR	11	11	10	6	11	10	9	11	9	8.2
MACR/LINC	5	5	4	3	5	5	4	5	4	**68.1**
CIP	1	1	1	1	1	1	1	1	1	3.8
LEV	6	6	6	5	5	6	6	6	6	12.3
MXF	6	6	5	2	6	5	5	6	5	10.8
QUINOLONES	3	3	3	2	2	3	3	3	3	**27.2**
CFL	2	3	2	4	2	2	3	3	1	10.5
CDR	6	6	5	4	6	5	5	5	4	13.3
CEPHALOSPORINS	4	4	3	3	3	3	3	3	2	**38.4**
DOX	1	1	1	1	1	1	1	2	1	4.3
TET										0.0
MNO										0.0
TETRACYCLINES	1	1	1	1	1	1	1	1	1	**4.3**
TMP-SMX	1	1	2	1	1	1	1	2	1	6.8
NIT										0.0

	EC	HI	KP	MC	PA	SA	SAg	SP	SPy	Weighted prescription rate (per 10,000 PY)
AMX	6	6	5	3	7	6	5	5	3	60.9
AMX-CLAV	8	8	6	2	8	7	5	6	5	32.3
PEN	1	1	1	1	1	1	1	1	0.2	1.4
PENICILLINS	6	6	5	3	7	5	5	5	3	**94.7**
AZM	6	6	5	3	6	5	5	5	4	52.5
CLI	2	2	1	1	2	1	1	2	1	2.8
CLR	11	11	10	7	11	10	9	11	9	7.5
MACR/LINC	5	5	5	3	5	5	4	5	4	**62.9**
CIP	1	1	1	1	1	1	1	1	1	3.7
LEV	6	6	6	5	5	6	6	6	6	11.6
MXF	6	6	5	2	6	5	5	5	5	9.8
QUINOLONES	3	3	3	2	2	3	3	3	3	**25.4**
CFL	3	3	3	4	2	2	3	3	1	9.9
CDR	6	6	5	4	6	5	5	5	4	12.5
CEPHALOSPORINS	4	4	3	3	3	3	3	4	2	**36.3**
DOX	2	2	2	1	2	2	2	2	1	4.2
TET										0.0
MNO										0.0
TETRACYCLINES	1	1	1	1	1	1	1	1	1	**4.2**
TMP-SMX	1	1	2	2	1	1	1	1	1	5.9
NIT										0.0

535

536

D. Prescribe nitrofurantoin for all cases of cystitis in women.



Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin, AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides, CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline, TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years